Skip to content

MaxCyte MXCT Accounts Payable

Accounts Payable at other companies

Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$133.1M-3.5%
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
$4.73M-17.6%
Rapid Micro Biosystems logo
Rapid Micro BiosystemsRPID
$4.67M+77.2%
PDE
Pro-Dex, Inc.PDEX
$5.25M-12.0%
Repligen logo
RepligenRGEN
$34.66M+28.7%
TEC
Bio-TechneTECH
$23.49M-25.8%

Other financials

Income statement

See full
Revenue$9.7M-7.1%
Gross profit$8.1M-9.1%
Operating income-$6.2M+49.7%
Net income-$4.8M+53.7%
EPS (diluted)-$0.04+60.0%

Balance sheet

See full
Cash & equivalents$14.6M-37.8%
Total debt$17.5M-7.1%
Total equity$167.9M-15.8%
Total assets$194.5M-15.4%

Cash flow

See full
Operating cash flow-$8.2M+43.3%
CapEx$72.0K-89.0%
Free cash flow-$8.2M+45.3%

Valuation

See full
Market cap$130.15M-46.8%
Enterprise value$133.08M-46.3%
P/S-2.8×

Profitability

See full
Gross margin80.5%-0.4pp
Operating margin-141.8%+6.4pp
Net margin-121.2%+12.3pp
FCF margin-90.9%+3.7pp

Returns & leverage

See full
Return on equity-21.3%+2.0pp
Debt / equity0.1×0.0×
Current ratio12×-0.2×

Where this comes from

Reported directly by MaxCyte in its filing.

Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.

The official record: MaxCyte’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about MaxCyte's accounts payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MaxCyte's accounts payable?
MaxCyte (MXCT) reported accounts payable of $1.2M in Q1 2026.
How has MaxCyte's accounts payable changed year-over-year?
MaxCyte's accounts payable decreased by 47.5% year-over-year, from $2.28M to $1.2M.
What is the long-term trend for MaxCyte's accounts payable?
Over 5 years (2020 to 2025), MaxCyte's accounts payable has grown at a 9.5% compound annual growth rate (CAGR), from $890.2K to $1.4M.
What does accounts payable mean?
Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.